Navigation Links
VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
Date:10/29/2009

s in animal studies. VIA will investigate the possibility of using the THR beta agonist in combination with statins for the treatment of hypercholesterolemia. In addition, in animal studies, insulin sensitization and glucose lowering were observed making this compound a possible treatment of patients with type 2 diabetes in combination with other diabetes medications.

About DGAT1

DGAT1 (diacylglycerol acyl transferase-1) is an enzyme that catalyzes triglyceride synthesis and fat storage. Triglycerides are the principal component of fat, which is the major repository for storage of metabolic energy in the body. Overweight and obese individuals have significantly greater triglyceride levels, making them more prone to diabetes and its associated metabolic complications. DGAT1 inhibitors are believed to be an innovative class of compounds that modify lipid metabolism. In studies of obese animals, DGAT1 inhibitors have been shown to induce weight loss and improve insulin sensitization, glucose tolerance and lipid levels. These observations suggest DGAT1 inhibitors may have the potential to treat obesity, diabetes and dyslipidemia. VIA intends to identify potential clinical candidates from the compounds in this program and determine which may be moved into further preclinical development.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need by reducing inflammation in plaque, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit:

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
2. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
3. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
4. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
5. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
6. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
7. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
9. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
10. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
11. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Los Angeles, CA (PRWEB) September 02, 2014 ... an article on its website titled “Why You Should ... more than 80 percent of the global population breathes ... droplets and particles of pollution lodge in the skin’s ... the body’s natural barrier to free radicals that may ...
(Date:9/2/2014)... women diagnosed with early-stage breast cancer in California, the ... and 2011, although this procedure was not associated with ... radiation, according to a study in the September 3 ... that surgery for the removal of one breast was ... other options examined in the study. , Randomized trials ...
(Date:9/2/2014)... within a few days of discharge do so principally because ... in other parts of the health care system, according to ... Annals of Emergency Medicine ( "Return Visits to the ... asked why they did not follow up as an outpatient, ... wait until their scheduled appointment or being instructed to return ...
(Date:9/2/2014)... Operators in the Community Services ... annually, arranging care and counsel for those in need. ... expected to derive $39.4 billion in revenue, which includes ... Over the five years through 2014-15, the subdivision is ... including growth of 4.1% in 2014-15. , As the ...
(Date:9/2/2014)... Steven Reinberg ... News) -- Stimulant medications -- such as Adderall, Ritalin ... in children, won,t stunt their growth, a new study ... height as adults," said study researcher Dr. Slavica Katusic, ... in Rochester, Minn. Katusic noted that results of ...
Breaking Medicine News(10 mins):Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3Health News:Discharged patients return to the ER because 'better safe than sorry' 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3
... first time, scientists report a link between eating nuts and ... metabolic syndrome (MetS), who are at high risk for heart ... and decreases feelings of hunger, makes people feel happier and ... nuts (raw unpeeled walnuts, almonds and hazelnuts) a day to ...
... University Medical Center and Nationwide Children,s Hospital have developed a ... of people born with an inherited, progressive form of blindness ... of a clinical trial investigating the use of gene therapy ... people worldwide. The trial is being conducted by researchers at ...
... (BMI)are important risk factors for gestational diabetes mellitus (GDM) particularly ... published today (02 November) in BJOG: An International Journal ... the link between maternal age, BMI and racial origin with ... other. Data were collected on 585,291 pregnancies in ...
... of Michigan Health System laboratory study reveals a key trigger ... a new treatment for those with sickle cell disease. ... early edition of the Proceedings of the National Academy ... episodes and organ damage that are common complications of sickle ...
... depends on diagnostic tests, diagnostic physicians have a responsibility ... or unexpected findings. According to an article selected as ... recent edition of the Journal of the American ... growth of diagnostic testing appears to be placing physicians ...
... News) -- A new surgical method that uses a natural ... less scarring and faster recovery for patients, according to the ... used in this type of procedure is located behind the ... surgeries to remove skull base tumors require incisions through the ...
Cached Medicine News:Health News:Benefits of nut consumption for people with abdominal obesity, high blood sugar, high blood pressure 2Health News:Ohio State researchers design a viral vector to treat a genetic form of blindness 2Health News:Age and BMI can predict likelihood of developing gestational diabetes new research suggests 2Health News:Age and BMI can predict likelihood of developing gestational diabetes new research suggests 3Health News:Researchers reveal potential treatment for sickle cell disease 2Health News:Diagnostic physicians at increased risk for medical malpractice claims due to communication failures 2Health News:New Technique to Remove Skull Tumors May Mean Less Scarring 2
(Date:9/2/2014)... commands the vital signs monitoring devices market with over ... . The North American and European vital signs monitors ... million, respectively, by the end of 2013. They have ... number of elderly people across these economies. The European ... owing to the rising demand for home health patient ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
Breaking Medicine Technology:Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2
... , HAMBURG , Feb. 3 ... Wound Therapy (NPWT) will assemble this week to develop a ... NPWT Expert Panel is drafting recommendations for a range of ... published clinical evidence.  Where published evidence is insufficient, the Panel ...
... Feb. 2 Celsis In Vitro, Inc. (Celsis IVT) ... XenoTech LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. ... Illinois in Chicago .  XenoTech and Sekisui Medical ... processes and methods performed by XenoTech associated with its in ...
Cached Medicine Technology:International NPWT Expert Panel Convenes in Hamburg 2International NPWT Expert Panel Convenes in Hamburg 3Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 2Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui 3
... Designed for the Anterior Segment The ... lens practitioners and ophthalmologists specializing in the anterior ... emergency rooms. Video- c-mount camera on the BD ... port. Standard magnification in 10 and 16 X ...
... FVL is a new functional test which ... Activated Protein C Resistance caused by the ... to other commercially available methods, Pefakit APC-R ... or S, Lupus Anticoagulants, Elevated FVIII levels, ...
... Used for venous pressure monitoring, blood ... fluids. Turbo-Flo polyurethane PICC line sets ... Rates, Micropuncture Introducer Needle, ... be trimmed to patient specific anatomy. ...
Assess serum Gc-globulin levels in patients with multiple trauma, fulminant liver failure, acetaminophen overdose, and sepsis....
Medicine Products: